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Objectives Our goal was to investigate the effects of percutaneous left ventricular assist device (pLVAD) support during
catheter ablation of unstable ventricular tachycardia (VT).
Background Mechanical cardiac support during ablation of unstable VT is being increasingly used, but there is little available
information on the potential hemodynamic benefits.
Methods Twenty-three consecutive procedures in 22 patients (ischemic, n  11) with structural heart disease and hemo-
dynamically unstable VT were performed with either pLVAD support (n  10) or no pLVAD support (intra-aortic
balloon pump counterpulsation, n  6; no support, n  7). Procedural monitoring included vital signs, left atrial
pressure, arterial blood pressure, cerebral perfusion/oximetry, VT characteristics, and ablation outcomes.
Results The pLVAD group was maintained in VT significantly longer than the non-pLVAD group (66.7 min vs. 27.5 min;
p  0.03) and required fewer early terminations of sustained VT for hemodynamic instability (1.0 vs. 4.0;
p  0.001). More patients in the pLVAD group had at least 1 VT termination during ablation than non-pLVAD
patients (9 of 10 [90%] vs. 5 of 13 [38%]; p  0.03). There were no differences between groups in duration of
cerebral deoxygenation, hypotension or perioperative changes in left atrial pressure, brain natriuretic peptide
levels, lactic acid, or renal function.
Conclusions In patients with scar-related VT undergoing catheter ablation, pLVAD support was able to safely maintain end-
organ perfusion despite extended periods of hemodynamically unstable VT. Randomized studies are necessary
to determine whether this enhanced ability to perform entrainment and activation mapping will translate into
a higher rate of clinical success. (J Am Coll Cardiol 2011;58:1363–71) © 2011 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.022A majority of patients with ventricular tachycardia (VT) in
the setting of structural heart disease have unstable VT (1).
As a result of this hemodynamic instability, less than
one-third of patients are suitable for ablation guided only by
mapping during VT (2), and with the greater use of effective
coronary reperfusion during myocardial infarction, this number
is further decreasing (3). Furthermore, most patients with
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accepted June 20, 2011.scar-related VT have significant left ventricular dysfunction
and other associated comorbidities that make them highly
susceptible to the hemodynamic collapse and impairments in
end-organ perfusion which can accompany unstable VT. As
such, activation and entrainment mapping is difficult, if not
impossible, for any extended period of time (1).
Theoretically, the use of mechanical cardiac assistance
support allows for detailed mapping of VT in such patients,
but there are limited data on the effects of these devices
during VT mapping and ablation. The intra-aortic balloon
pump (IABP) is the most commonly used temporary cardiac
assist device, but this is a passive system that, in any event,
has marginal effectiveness for hemodynamic support during
VT. Specifically, low systolic blood pressure, elevated heart
rate (110 beats/min), and the need for accurate synchro-
nization with the cardiac cycle (electrocardiographic gating)
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neous left ventricular assist de-
vices (pLVADs) do not appear to
be limited by these factors and
ultimately could facilitate map-
ping and ablation of ongoing VT,
but there are limited data to sup-
port their use during VT ablation
(5). We hypothesized that by
maintaining near-normal hemo-
dynamics and end-organ perfu-
sion, a pLVAD would prove to
be a viable option for mechanical
cardiac assistance by allowing for
a greater duration of mapping
and ablation during ongoing VT.
Methods
All procedures were performed
after obtaining written informed
consent according to the institu-
tional guidelines at the Mount Sinai Medical Center (New
York, New York). This study was approved by our institu-
tional review board.
Study population. From May 2010 to November 2010, a
total of 23 consecutive VT ablations were performed in 22
patients with structural heart disease and who had at least 1
episode of hemodynamically unstable VT (defined as a
mean arterial pressure 45 mm Hg). All patients were
referred to us for further management of either sustained
monomorphic ventricular tachycardia (MMVT) and/or re-
current implantable cardioverter-defibrillator (ICD) shocks.
Patients underwent catheter ablation of VT with either
pLVAD support (n  10) or no pLVAD support (IABP
ounterpulsation, n  6; no mechanical support, n  7).
Physician preference, with knowledge of the patient’s un-
derlying substrate and/or clinical VT characteristics, was the
basis for using a particular percutaneous device (pLVAD vs.
IABP). Peripheral arterial disease was the precluding factor
in 57% (4 of 7) of the patients who did not receive any
mechanical support; the remainder in this group did not
receive mechanical support secondary to physician preference.
Procedural details. All procedures were performed under
general anesthesia with endotracheal intubation. An in-
dwelling arterial catheter was inserted into the radial artery
for continuous blood pressure monitoring. Phenylephrine
was used for blood pressure support as necessary. Cerebral
tissue oxygen saturation (SctO2) was noninvasively mea-
ured and recorded with an absolute cerebral oximeter
FORE-SIGHT, CASMED, Branford, Connecticut). The
echnological background of SctO2 monitoring has been
escribed elsewhere (6). Baseline SctO2 values were re-
corded 5 min after endotracheal intubation with an 80% to
100% fraction of inspired oxygen and then automatically
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LAP  left atrial pressure
MMVT  monomorphic
ventricular tachycardia
pLVAD  percutaneous left
ventricular assist device
SctO2  cerebral tissue
oxygen saturation
VT  ventricular
tachycardiaevery 2 s thereafter.Noninvasive bispectral (BIS) electroencephalogram anal-
ysis (Aspect Medical Systems, Inc., Newton, Massachu-
setts) was used in all patients throughout the case. The BIS
index is displayed as a numeric value ranging from 0 to 100;
values of 40 to 60 are typically associated with adequate
levels of anesthesia, but acute reductions from baseline may
indicate cerebral hypoperfusion (7).
Cardiac assist devices. For patients treated with an IABP
(Datascope Corporation, Mahwah, New Jersey), the cath-
eter was inserted percutaneously through an 8-F introducer
sheath into the femoral artery. Once correct positioning was
confirmed (tip 2 to 3 cm from the left subclavian artery), the
balloon was programmed to 1:1 assistance throughout the
case. For patients treated with a pLVAD (Impella 2.5,
ABIOMED, Inc., Danvers, Massachusetts), the catheter
was inserted percutaneously through a 13-F sheath in the
femoral artery (usually the left femoral artery). The device
was positioned in the left ventricle as previously described
(8), and the maximum performance level of 8 (1.9 to 2.5
l/min, 50,000 rpm) was maintained throughout the case,
unless electromagnetic interference (EMI) (see Results sec-
tion) necessitated temporary adjustments. In one case, the
Impella LP 2.5 was implanted after programmed stimula-
tion in a patient with overall preserved ventricular function
but after inducing hemodynamically unstable VT; other-
wise, in all cases of either pLVAD or IABP, the device was
implanted at the beginning of the procedure.
The pre-close technique for arteriotomy site closure was
used in all pLVAD cases (Perclose ProGlide, Abbott
Laboratories, Abbott Park, Illinois) (9).
Electrophysiological evaluation and ablation strategy.
Catheters were inserted in usual fashion and included a
mapping catheter in the right ventricle and a 10-F linear
phased-array intracardiac ultrasound probe (AcuNav, Bio-
sense Webster, Inc., Diamond Bar, California). All map-
ping was performed with a hybrid magnetic/impedance-
based electroanatomic mapping system (Carto 3, Biosense
Webster, Inc.) and a 3.5-mm externally irrigated ablation
catheter (Navistar ThermoCool, Biosense Webster, Inc.).
Left ventricular endocardial mapping was performed in
91% (21 of 23) of the procedures using a transseptal
approach with an 8.5-F steerable sheath (Agilis, large curve,
St. Jude Medical, St. Paul, Minnesota). Transseptal access
was not obtained in 2 cases because endocardial mapping
involved only the right ventricle. In the remaining 21 cases
for which left atrial access was obtained, the mean left atrial
pressure (LAP) was measured at the beginning and end of
the case. If mechanical support was being used, the starting
LAP was recorded at the beginning of the case after at least
5 min at the highest levels of support (IABP at 1:1
augmentation or Impella 2.5 at performance level 8 [50,000
rpm]). At the conclusion of the procedure, the mean LAP
was again measured at the highest level of support. Epicar-
dial mapping was performed in 12 cases (percutaneous
subxiphoid puncture approach in 9 patients; surgical subxi-
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September 20, 2011:1363–71 VT Ablation Using LVADlation with heparin was instituted to maintain an activated
clotting time (ACT) of 250 to 300 s. The ACT target was
not modified for the pLVAD group, as the recommended
ACT level (250 s) for the device used in this series falls
within the same therapeutic range as our standard antico-
agulation protocol for VT mapping and ablation (8). In
cases in which epicardial access was obtained (always before
the transseptal access or pLVAD insertion), anticoagulation
was not administered until pericardial drainage/bleeding
was absent.
Electrophysiology testing and radiofrequency catheter
ablation were performed using standard techniques and
included a combination of entrainment and/or activation
mapping (if possible), pace mapping, and sinus rhythm–
guided substrate modification. In all patients, routine labo-
ratory tests and brain natriuretic peptide levels were mea-
sured immediately before and 1 day after the procedure.
Arterial lactate levels were measured immediately before
and at the conclusion of the procedure. The VT burden was
defined as the total duration of all episodes of MMVT,
lasting 10 s or more, during the course of the procedure.
Burst ventricular pacing that did not result in MMVT was
not included. Early terminations of MMVT, while mapping
tachycardia, with either pace-termination or direct current
cardioversion, were also quantified. Episodes of ventricular
fibrillation and polymorphic VT (which were universally
terminated by immediate cardioversion) were excluded.
Recurrent VT during follow-up was defined as either
sustained MMVT or VT/ventricular fibrillation–requiring
ICD therapy within 3 months of the procedure.
Clinical CharacteristicsTable 1 Clinical Characteristics
Characteristic All Patients (N  2
Clinical








Prior CABG 12 (52%)
NYHA functional class I–II 14 (61%)
NYHA functional class III–IV 9 (39%)
ICD shock 20 (87%)
LVEF (%) 31 16
LVEDD 6.0 1.0
RV dysfunction 1.2 1.1
Antiarrhythmic medications
Beta-blocker 16 (70%)
Class 1B antiarrhythmic agents 7 (30%)
Class III antiarrhythmic agents 21 (91%)
Values are mean  SD or n (%).
CABG  coronary artery bypass graft; CKD  chronic kidney diseaseLVEDD left ventricular end-diastolic diameter; LVEF left ventricular ejection fr
ventricular assist device; RV  right ventricular.Statistical analysis. Comparisons of continuous variables be-
tween groups with or without pLVAD support were made using
the Student t test (mean SD) with the Levene test for equality
of variance used to confirm homogeneity. Variables with non-
normally distributed data were expressed as median (interquartile
range), and statistical comparisons for these variables were made
using the Mann-Whitney U test. Categorical variables were
compared using the chi-square test, or, when fewer than 5
expected outcomes were expected per cell, the Fisher exact test.
Integrated SctO2 (area under the curve) for SctO2 55% was
alculated as: minutes  desaturation points 55%. A relative
ecrease in SctO2 from baseline was calculated as: percent de-
crease from baseline (baseline – current value)/baseline 100.
wo-sided p  0.05 was considered indicative of statistical
ignificance. Statistical calculations were performed using SPSS
ersion 12.0 (SPSS Inc., Chicago, Illinois).
esults
atient characteristics. The baseline characteristics of the
groups are shown in Table 1. There was no significant
ifference between the groups with regard to age, history of
ypertension, diabetes, ischemic cardiomyopathy, coronary
rtery bypass grafting, left ventricular ejection fraction, left
entricular end-diastolic diameter or baseline renal function.
here was no difference between the 2 groups in pre-
rocedural antiarrhythmic medication use: Class III antiar-
hythmic medications (most commonly, amiodarone) and
eta-blockers were used in 90% and 70% of the entire
atient cohort, respectively. There was no significant differ-
pLVAD (n  10) No pLVAD (n  13) p Value
64.1 13.4 66.8 16.0 0.66
10 (100%) 13 (100%) —
5 (50%) 5 (39%) 0.58
0 (0%) 3 (23%) 0.23
6 (60%) 3 (23%) 0.07
58 32 64 20 0.61
6 (60%) 5 (39%) 0.41
5 (50%) 7 (54%) 0.89
4 (40%) 10 (77%) 0.10
6 (60%) 3 (23%) 0.10
8 (80%) 12 (92%) 0.56
26 11 35 18 0.18
6.2 1.1 5.9 1.0 0.53
1.0 1.1 1.3 1.1 0.51
6 (60%) 10 (77%) 0.65
4 (40%) 3 (23%) 0.65
9 (90%) 12 (92%) 1.000
glomerular filtration rate; ICD  implantable cardioverter-defibrillator;3)
; GFR 
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pLVAD and non-pLVAD groups (NYHA functional class
III or IV: 6 [60%] vs. 3 [23%], p  0.10).
Electrophysiological study and VT burden. As shown in
Table 2, epicardial access was obtained in 48% (11 of 23) of
all cases and was similar between the 2 groups (n 6 [60%]
in the pLAVD group vs. 5 [39%] in the non-pLVAD
group; p  0.41). The duration of the procedure was
ignificantly longer in the pLVAD group compared with
he non-pLVAD group (528.3 min vs. 407.3 min; p 
.01). Two or more VT morphologies were induced in 96%
22 of 23) of the procedures, and there was no significant
ifference between the pLVAD and non-pLVAD groups
ith regard to the number of inducible MMVTs (3.4 vs.
.8; p  0.26) or mean tachycardia cycle length (395.1 ms
s. 395.8 ms; p  0.99) (Table 2). The pLVAD group had
a significantly higher VT burden (defined as the total time
in VT during the procedure) compared with the non-
pLVAD group (66.7 min vs. 27.5 min; p  0.03) and
required fewer early terminations of sustained MMVT for
hemodynamic instability during entrainment/activation
mapping (1.0 vs. 4.0; p  0.001). Representative examples
of MMVT with and without pLVAD support are shown in
Figures 1 and 2, respectively.
VT ablation outcome. There were a total of 34 VTs in 10
patients and 38 VTs in 13 patients in the pLVAD and
non-pLVAD groups, respectively. Of these, 21 VTs (13 in
the pLVAD group and 8 in the non-pLVAD group) were
terminated by radiofrequency energy delivery during ongo-
ing VT (i.e., ablation during VT). On a per-patient basis, at
least 1 VT was terminable by energy delivery during
ongoing VT in 9 of 10 (90%) patients and 5 of 13 (39%)
patients in the pLVAD and non-pLVAD groups, respec-
tively (p  0.03) (Table 2). There was no difference in total
duration of radiofrequency ablation in the pLVAD and
non-pLVAD groups (27.9  13.6 min vs. 21.8  9.2 min
[p  0.23], respectively). Inducibility for VT was assessed







VT cycle length (ms)
Duration of time spent in VT (min)
DCCV/pace termination of MMVT
No. of RF-mediated terminations of MMVT per patient
No. of patients with at least 1 radiofrequency-mediated termination of MMVT
Total duration of ablation (min)
Inducible for MMVT at conclusion of procedure*
Recurrent VT/VF within 3 months
Values are n (%), mean  SD, or median (interquartile range). Statistically significant values are in
(20 of 23) of the entire cohort (8 of 10 from the pLVAD group and 12 of 13 the non-pLVAD groupCL cycle length; DCCV direct current cardioversion; MMVTmonomorphic ventricular tachycardia;
tachycardia.by programmed ventricular stimulation at the end of the
procedure in 87% (20 of 23) of the entire cohort (8 of 10 of
the pLVAD group and 12 of 13 of the non-pLVAD group).
There was no difference in the number of patients who
remained inducible for MMVT in the pLVAD and non-
pLVAD groups (2 of 8 [25%] vs. 4 of 12 [33%]; p  0.05,
respectively). During follow-up, 3 (30%) patients in the
pLVAD group and 4 (31%) patients in the non-pLVAD
group had recurrences of sustained MMVT and/or appro-
priate ICD therapy (p  0.97).
Hemodynamics and surrogates of end-organ perfusion. Al-
though the mean arterial pressure was similar in both
groups, systolic blood pressure was lower and diastolic
pressure was higher in the pLVAD patients compared with
the non-pLVAD patients (105.5 mm Hg vs. 117.9 mm Hg
[p  0.04] and 62.8 mm Hg vs. 50.5 mm Hg [p  0.002],
respectively) (Table 3). Baseline mean LAP was increased
for the entire cohort (14.2 4.8 mm Hg), and there was no
statistical difference between the pLVAD group and the
non-pLVAD group with regard to the post-procedure
elevations in mean LAP (2.5  4.4 mm Hg vs. 5.4  7.7
mm Hg; p  0.32). Similarly, there was no statistical
difference between the 2 groups in the peri-procedural
changes in brain natriuretic peptide levels (505 [73 to
732] vs. 221 [152 to 730]; p  0.76), arterial lactate levels
(0.5  0.7 mmol/l vs. 0.4 0.5 mmol/l; p 0.58), or renal
function (glomerular filtration rate3 13 vs. 5 11; p
0.11).
Duration of cerebral tissue deoxygenation was similar for
both groups, whether comparing the integrated (area under
the curve) SctO2 55%, total duration (in minutes) of
ctO2 55%, or relative reductions of 20% from postin-
ubation baseline values (Table 3). There was no difference
etween the mean BIS values in the pLVAD group com-
ared with the non-pLVAD group (52.6 vs. 49.6; p 0.40)
r the duration the BIS value was30 (3.6 min vs. 6.7 min;
 0.69).
tients (n  23) pLVAD (n  10) No pLVAD (n  13) p Value
1 (48%) 6 (60%) 5 (39%) 0.41
8 (35%) 4 (40%) 4 (31%) 0.69
3 (13%) 2 (20%) 1 (8%) 0.56
9.1 101.7 528.3 105.5 407.3 62.1 0.01
3.0 1.3 3.4 1.4 2.8 1.2 0.26
395.5 395.1 395.8 0.99
3.5 42.7 66.7 38.3 27.5 38.7 0.03
5 (1.0–4.25) 1.0 (0.0–1.5) 4.0 (2.5–5.0) 0.001
0 (0.0–2.0) 1.0 (1.0–2.0) 0.0 (0.0–1.0) 0.03
4 (61%) 9 (90%) 5 (39%) 0.03
4.6 11.5 27.9 13.6 21.8 9.2 0.23
6 (30%) 2 (25%) 4 (33%) 1.000
7 (30%) 3 (30%) 4 (31%) 0.97
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September 20, 2011:1363–71 VT Ablation Using LVADElectromagnetic interference. EMI during VT entrain-
ment mapping was classified as follows: mild if noted by the
electroanatomic mapping system but no intervention re-
quired; moderate if it necessitated reducing the pLVAD
erformance level; or severe if it required temporarily turn-
ng off the pLVAD. Mild EMI occurred in 6 cases,
oderate in 3, and severe in 1. In cases with mild EMI,
ntrainment mapping was continued. For the moderate
MI cases, pLVAD performance level was titrated down,
enerally from 50,000 rpm (1.9 to 2.5 l/min) to 35,000 rpm
0.4 to 10.0 l/min), which either resolved or decreased EMI
nough to continue mapping (Fig. 3). In the isolated case of
evere interference, the pLVAD was temporarily turned off,
hich resolved the EMI. Magnetic interference did not
ave a discernible effect on the pLVAD performance.
omplications. There were 2 major complications (9%) in
he entire cohort, both related to pericardial tamponade in
atients who had undergone epicardial mapping/ablation.
ne patient in the pLVAD group developed pericardial
amponade approximately 6 h into the procedure, due to a
-mm laceration on the anterior surface of the right ventri-
le. Although the pLVAD itself was not the cause of the
Figure 1 VT Ablation With pLVAD Support
A 47-year-old man with nonischemic cardiomyopathy and severe left ventricular dy
assist device (pLVAD) support during ablation for ventricular tachycardia (VT). (A)
ing extensive inferolateral scarring. (B) Bilateral cerebral tissue oxygen saturation
waveform, and right ventricular mapping catheter of the VT before, during, and afte
sure, this episode of VT during which entrainment mapping was performed continu
VT during this procedure was 91 min. AV  aortic valve; RF  radiofrequency.yocardial laceration, one cannot rule out the possibilitythat a contributing factor to the pericardial effusion was
some degree of hesitancy by the operator to rapidly reverse
systemic anticoagulation due to the pLVAD. Conversely, 1
patient in the IABP group also developed pericardial tam-
ponade approximately 30 min after completion of the
procedure. This was discovered after removal of the IABP
and the transseptal and epicardial access sheaths, at which
time protamine had already been administered for reversal
of systemic anticoagulation. In this latter case, there was no
source of bleeding identified during surgical exploration.
Both patients underwent successful sternotomies and con-
tinue to do well 3 months after the procedures. There
were no vascular access site injuries or groin hematomas in
any of the patients that required either intervention, holding
of anticoagulation therapy, or transfusion of blood products.
Discussion
This is the largest study on the effects of mechanical support
for hemodynamic maintenance during mapping and abla-
tion of unstable VT and the first to evaluate the use of
on (left ventricular ejection fraction 26%) underwent percutaneous left ventricular
ntricular epicardial bipolar voltage map (posteroanterior projection) demonstrat-
) curves of the case. (C to E) Surface electrograms, arterial blood pressure
essful entrainment mapping and termination. Despite hypotensive blood pres-




ed fornoninvasive neuromonitoring modalities such as cerebral
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VT Ablation Using LVAD September 20, 2011:1363–71oximetry in this setting as an indicator of end-organ
perfusion during VT ablation.
Main findings. The pLVAD group was maintained in VT
nearly 2.5 times longer than the non-pLVAD group and
required less premature terminations of ongoing VT. Im-
portantly, the significantly greater duration of VT was
possible without any comparative evidence of tissue hypo-
perfusion or end-organ damage.
The retrospective nature of this study precludes robust
conclusions on the effectiveness of pLVAD use during VT
ablation. However, there were some very interesting obser-
vations in this study that suggest benefit. First, despite a
significantly greater duration of time spent during VT in the
pLVAD group (66.7 min vs. 27.5 min; p  0.03), there
were no differences in the post-procedural measurable out-
comes such as renal function or LAP. Second, there was a
significantly diminished need for early VT termination of
sustained VT for hemodynamic instability in the pLVAD
group (0.9 vs. 3.9 terminations/procedure; p  0.001). This
was likely a reflection of the hemodynamic maintenance-
capabilities afforded by the pLVAD. Finally, the majority of
the patients in the pLVAD group (90%) had at least 1 VT
Figure 2 VT Ablation Without pLVAD Support
A 65-year-old male with ischemic cardiomyopathy and severe left ventricular ejecti
endocardial bipolar voltage map (posteroanterior projection) demonstrating extens
metry). (C and D) Surface electrograms, arterial blood pressure waveform, and rig
67% to 49% in 2 min, necessitating external cardioversion. The patient required
case. Dobutamine infusion and intravenous diuretics were instituted for pulmonary
dia during this procedure was 26 min. DCCV  direct current cardioversion; MV that was terminable by radiofrequency energy delivery dur-ing ongoing VT. This finding compared favorably to the
38% value observed in the non-pLVAD group. In toto,
these observations provide the scientific basis for a prospec-
tive randomized controlled trial of the use of pLVAD
during catheter ablation of scar-related VT.
Electromagnetic interference. From a feasibility perspec-
tive, interference between the electroanatomic mapping
system and the pLVAD was not prohibitive during the
majority of the cases. Not surprisingly, the EMI was
greatest during mapping in the ventricular outflow tracts
because of the proximity to the magnetic motor of the
pLVAD device. It is also important to note that all of the
left ventricular mapping in this study was performed using a
transseptal approach. In other procedures we have per-
formed using a retrograde mapping approach since this
patient cohort, we have noted additional electrical noise on
the mapping electrogram channels.
Safety of pLVAD. The major potential safety issues one
might expect with the pLVAD are avulsion of the aortic
valve, vascular injury at the point of insertion into the
femoral artery, hematoma/pseudoaneurysm/retroperitoneal
bleeding after device removal, and stroke/systemic embo-
function (17%) underwent VT ablation without pLVAD support. (A) Left ventricular
roposterior scar. (B) Bilateral SctO2 curves (based on transcranial cerebral oxi-
tricular mapping catheter before and during unstable VT. SctO2 dropped from
rnal cardioversions for unstable monomorphic ventricular tachycardia during the
a at the end of the case. The total duration of monomorphic ventricular tachycar-
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September 20, 2011:1363–71 VT Ablation Using LVADin this series is reassuring. Use of intracardiac echocardiog-
raphy during pLVAD insertion, the suture-based technique
to pre-close the arteriotomy site, and close attention to
anticoagulation likely contributed to the good safety profile
observed in this series.
Hemodynamics and cerebral oximetry. Pulse oximetry
monitoring, which requires pulsatile flow and adequate
peripheral perfusion, is a relatively late warning sign of
Hemodynamics and Surrogates of End-Organ PerfusionTable 3 Hemodynamics and Surrogates of End-Organ Perfusion
Parameter All Patients (N  23)
MAP
Mean (mm Hg) 75.2 5.8
Time 55 mm Hg (s) 1,223 (739–1,710)
Time 50 mm Hg (s) 713 (334–983)
SBP
Mean (mm Hg) 112.6 14.2
Time 100 mm Hg (s) 7,388 (3,683–10,568)
Time 70 mm Hg (s) 668 (338–2,115)
DBP
Mean (mm Hg) 55.8 9.8




Integrated SctO2 55% (min %)
Left 45.9 134.0
Right 21.9 63.1






Time BIS index 30 (min) 5.4 12.4
Laboratory and left atrial pressure
BNP
Baseline 505 (208 to 864)
Post-procedure 921 (605 to 1,664) [505 (148 to 775)] 90
LAP
Baseline 14.2 4.8
Post-procedure 18.2 6.4 [4.0 6.4]
Lactate
Baseline 0.8 0.4
Post-procedure 1.3 0.5 [0.5 0.6]
BUN
Baseline 26.6 16.0
Post-procedure 23.6 15.0 [–3.1 5.9]
Cr
Baseline 1.5 0.8
Post-procedure 1.5 0.8 [–0.02 0.24]
GFR
Baseline 62 26
Post-procedure 64 28 [2 12]
Values are mean  SD or median (interquartile range). Numbers within brackets after post-p
pre-operatively to 1 day post-operatively (except for left atrial pressure and lactate, which were m
BIS bispectral; BNP brain natriuretic peptide; BUN blood urea nitrogen; Cr creatinine; D
arterial pressure; pLVAD  percutaneous left ventricular assist device; SBP  systolic blood pressdeoxygenation (13). However, the utility of SctO2 (which ddoes not require pulsatile flow) for the early detection of
impaired tissue oxygenation and perfusion has been demon-
strated in a variety of clinical settings (14,15). By using the
brain as an index organ, interventions to improve cerebral
oxygenation had systemic benefits. Similarly, we propose that
during VT ablation, SctO2 may serve as a better marker of
emodynamic stability than blood pressure. Limitations of this
echnique at this point are that safe lower limits have not been
pLVAD (n  10) No pLVAD (n  13) p Value
76.9 7.0 73.9 4.7 0.26
,305 (773–3,675) 1,200 (739–1,508) 0.55
690 (338–2,790) 750 (311–938) 0.67
105.5 9.6 117.9 15.1 0.04
,465 (7,508–14,625) 6,113 (1,931–8,250) 0.01
,460 (720–4,703) 488 (281 to 855) 0.04
62.8 7.1 50.5 8.1 0.002
150 (60–518) 308 (79–2,651) 0.36
10.2 23.4 8.7 25.4 0.89
5.3 10.9 4.8 15.2 0.93
47.8 131.1 44.3 142.1 0.95
23.7 54.8 20.5 71.1 0.91
18.1 39.6 10.8 28.2 0.62
10.2 29.8 7.1 22.4 0.78
52.6 6.6 49.6 5.3 0.40
3.6 6.3 6.7 15.8 0.69
450 (203 to 853) 630 (144 to 1711)
7 to 952) [505 (–73 to 732)] 945 (293 to 2,263) [221 (152 to 730)] 0.76
14.3 3.9 14.2 5.7
.8 5.3 [2.5 4.4] 19.5 7.2 [5.4 7.7] 0.32
0.8 0.5 0.9 0.3
.4 0.5 [0.5 0.7] 1.3 0.6 [0.4 0.5] 0.58
30.2 17.5 23.8 14.9
 14.9 [–4.6 8.2] 21.8 15.4 [–2.1 3.6] 0.41
1.8 1.1 1.3 0.5
.8 1.1 [–0.01 0.29] 1.3 0.5 [–0.03 0.22] 0.86
58 32 64 20
6 29 [–3 13] 69 27 [5 11] 0.11
e values are mean  SD or median (interquartile range) of change from respective baseline
d immediately post-operatively). Statistically significant values are indicated in bold.
iastolic blood pressure; GFR glomerular filtration rate; LAP left atrial pressure; MAPmean
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VT Ablation Using LVAD September 20, 2011:1363–71although a strict protocol by which to prematurely terminate
VT was not used, we generally consider early termination of
VT if the SctO2 value trends below 55% (16). Although
stablished hemodynamic monitoring modalities such as arte-
ial blood pressure and pulse oximetry should still be included
n the decision-making process, advances in neuromonitoring
rovide valuable information of adequate tissue perfusion
uring unstable VT.
tudy limitations. By virtue of the retrospective nature of
his study, we were unable to quantify the true difference
etween the 2 groups with respect to duration of entrain-
ent mapping/activation, only the length of time the
atients were in VT. Furthermore, the nonrandomized
ssignment of patients to 1 particular class of support was
ased on physician preference, and in 4 cases no support was
sed secondary to peripheral arterial disease. The relatively
mall number of patients and abbreviated follow-up period
recludes a relevant comparative assessment of clinical
utcome. Regarding the neuromonitoring with cerebral
ximetry and BIS, this retrospective study does not attempt
o establish safe limits that can be seen as lower thresholds
Figure 3 EMI During Mapping of the PTI
Electromagnetic interaction between the electroanatomic mapping system and the
dependent VT. (A) Right anterior oblique (RAO) projection of the pLVAD across the
the PTI. (B to D) Demonstration of the incremental degree of electromagnetic inte
(P) level 2 (B) to level 4 (C) to level 8 (D). At lower performance levels, mapping
position appears unstable, and mapping is not possible. PV  pulmonic valve; TVor VT termination. A fundamental question raised by this fesearch is whether a combined approach of entrainment
apping followed by substrate modification (the strategy
acilitated by the pLVAD) is truly superior to a purely
ubstrate modification strategy. In addition, it is important
o recognize both the additional time required to implant
nd remove the pLVAD (approximately 10 to 30 min,
epending on operator experience), and the additional cost
t adds to the procedure (approximately $25,000). Whether
hese additional factors are overall in favor or against use of
he pLVAD for VT ablation can only be definitively
valuated by prospective randomized trials.
onclusions
n patients with scar-related VT, percutaneous LVAD
upport is able to safely maintain end-organ perfusion
espite extended periods of hemodynamically unstable VT
o allow for detailed activation and entrainment mapping.
s identified by termination by ablation during ongoing
T, this translated to a high rate of identification of the
ritical VT isthmus. This provides the scientific basis for
in a patient with cardiac sarcoid and sustained pulmotricuspid isthmus (PTI)-
valve and the ablation catheter in the right ventricle, with its tip positioned on
ce that occurred with titration of the pLVAD performance level from performance
significantly affected. At the highest performance level (8), the ablation catheter




 tricuture prospective randomized clinical outcome studies.
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